close-up-of-the-back-of-a-casually-dressed-woman close-up-of-the-back-of-a-casually-dressed-woman-in-pharmacy

Who We Are

We answer the “what” and the “why” of drug coverage, reimbursement and overall market access.

About MMIT

MMIT is regarded as a trusted go-to-market partner that identifies barriers to patient access and helps coordinate major stakeholders to move therapies from pipeline to patient—answering the “what” of how payers cover therapies and the “why” behind those decisions. MMIT’s product portfolio has been built by listening to our clients, and with expert teams of pharmacists, clinicians, data specialists and market researchers who provide foresight, clarity and confidence. This is the hallmark of who we are and who we will always be.

More than two decades ago, MMIT (Managed Markets Insight & Technology, LLC) began as a division of Medi-Media, an agency supporting pharmaceutical clients in key areas of commercialization.

In 2016, MMIT acquired Atlantic Information Services (AIS), the creator of the Directory of Health Plans and leading healthcare publications. Three years later, MMIT acquired Zitter Health Insights, a provider of market access insights and solutions for specialty drugs with the longest-running, most robust panel of active P&T members to help answer the “why” of market access. And that same year, MMIT acquired RJ Health, the market leader in pricing and coding solutions for infusion drugs covered under the medical benefit.

In 2022, MMIT joined forces with other market-leading pharmaceutical-solutions providers—Evaluate, Panalgo and The Dedham Group—to launch Norstella, which aims to deliver must-have answers for critical strategic and commercial decision-making along the entire drug development journey.

Contact Us

For Those Familiar
with Market Access

We answer the “what” and the “why” related to drug coverage and reimbursement.

MMIT brings transparency to pharmacy and medical benefit information, partnering with pharmacy benefit managers (PBMs), payers and pharmaceutical manufacturers from pharmacy and therapeutics (P&T) to point of care. We analyze market access trends and market readiness challenges while providing brand and market access solutions to navigate the rapidly changing healthcare market.

MMIT answers the “what” and the “why” related to drug coverage and reimbursement.

MMIT answers the “what” and the “why” related to drug coverage and reimbursement.

For Those New to
Market Access

We leverage technology, research and industry experts to make sense of how and why specific pharmaceutical drugs are covered. Physicians and pharmacies use our data and applications to understand what drugs are available to patients and how they are covered by health plans. Pharmaceutical manufacturers trust our data to understand how their drug and competitive drugs are covered, which helps forecast performance and fine-tune strategy.



MMIT has been 100% focused on market access for decades. We combine deep domain expertise around drug coverage with innovative technology and trusted data to answer key business questions related to access. MMIT data is trusted by US physicians and sourced through a combination of direct partnerships with payers/PBMs and a technology infrastructure, powered by smart business logic, artificial intelligence and human validation.


Acquired in early 2019, Zitter Insights is a division of MMIT that brings market research and helps address the “why” of market access. Our Zitter Insights panel represents top health plans, PBMs and IDNs to provide meaningful insights to our clients.


AIS Health, acquired in 2016, is a publishing and information company that has served the health care industry for more than 30 years. Our mission is to provide our readers with an actionable understanding of the business of health care and pharmaceuticals.


RJ Health Solutions is the market leader in pricing and coding solutions for infusion drugs covered under the medical benefit. RJ expanded our reach while also providing us with the ability to support pricing and coding transparency and strategic reimbursement services for pharma.